Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Our Therapies
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jess Rowlands

    Head of Corporate Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

Goldman Sachs 44th Annual Global Healthcare Conference

  • Read more about Goldman Sachs 44th Annual Global Healthcare Conference

BofA Securities 2023 Health Care Conference

  • Read more about BofA Securities 2023 Health Care Conference

bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events

  • Read more about bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events

bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

  • Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

  • Read more about bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

bluebird bio 4th Quarter & Full Year 2022 Earnings Call

  • Read more about bluebird bio 4th Quarter & Full Year 2022 Earnings Call

Jack Allen

    Jack Allen
    Baird

    bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

    • Read more about bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

    bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

    • Read more about bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

    bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference

    • Read more about bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference

    Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page Next ›
    • Last page Last »
    Subscribe to

    Quick Links

    • Patients & Advocacy
    • Investors & Media
    • Careers
    • Contact Us

    CONTACT INFO

    info@bluebirdbio.com

    clinicaltrials@bluebirdbio.com

    investor@bluebirdbio.com

    medinfo@bluebirdbio.com

    Live - Terms & Privacy

    • Terms of Service
    • Privacy Policy
    • Cookie Notice
    • Sitemap
    © 2023 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

    Live - Social Links